Cancer Research
– Freenome examines thirty years of studies to understand differences in predictors of adherence across care settings– Recent studies highlight increased awareness of patient environment and clinical site factors as key predictors of adherence Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 15, 2022 /PRNewswire/ — Freenome, a privately held biotech company, presented research at the American Society…
Read More
Clinical Study Expected to Begin in 2022 to Investigate the Safety and Efficacy of IOV-4001 to Deliver TIL and PD-1 Inhibition within a Single Cancer Therapy First Genetically Modified Iovance TIL Therapy Leverages TALEN® technology Licensed from Cellectis to Inactivate PD-1 Expression Excerpt from the Press Release: SAN CARLOS, Calif., March 15, 2022 (GLOBE NEWSWIRE) — Iovance…
Read More
Clinical Guidelines Support Adoption of Urinary Biomarker Tests with High Sensitivity and Negative Predictive Values for High-Grade Disease to Replace and/or Postpone Cystoscopies in Low- and Intermediate-Risk NMIBC Publication of Meta-Analysis in European Urology Oncology Showed Bladder EpiCheck has Best Performance Amongst Guideline-Recommended Urinary Biomarker Tests Excerpt from the Press Release: SAN DIEGO & REHOVOT,…
Read More
Excerpt from the Press Release: WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene Corporation and Thomas Jefferson University announced the online publication of the manuscript, “Tadalafil enhances immune response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma”in the American Association for Cancer Research journal Clinical Cancer Research.The study revealed pretreatment head and neck squamous cell carcinoma specimens contain…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., March 16, 2022 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology Research of preclinical data for its lead molecule WTX-124, a systemically delivered Interleukin-2 (IL-2) INDUKINE™ molecule. The…
Read More
Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial, which evaluated cabozantinib (CABOMETYX®) in combination with atezolizumab versus sorafenib in patients with previously untreated advanced hepatocellular carcinoma (HCC). The final analysis…
Read More
– Results suggest that mesothelin-targeted TriKE can work alongside current standard of care and provide benefit even in the hypoxic environment of a solid tumor Excerpt from the Press Release: BRISBANE, Calif., March 9, 2022 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary tri-specific…
Read More
NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia Excerpt from the Press Release: CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative…
Read More
The Company Also Announced Immunotherapy Pioneer Dr. Michael Jensen as Founding Advisor Broad research collaboration focuses on BrainChild program, a suite of five multiplex chimeric antigen receptors (CARs) that initially targets pediatric central nervous system (CNS) malignancies with limited therapeutic options. Cellevolve will also leverage Seattle Children’s renowned Cure Factory® facility for early clinical Good…
Read More
– Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC – – PFS and OS benefits were observed across all PD-L1 expression subgroups, including in patients with low PD-L1 expression – Excerpt from the Press Release: REDWOOD CITY, Calif., and SHANGHAI, China, March 04, 2022 (GLOBE NEWSWIRE) —…
Read More